HIMS Stock Hims & Hers Health, Inc.
Today’s call · HIMS
All live ideas →5 of 6 technical checks lean bearish
HIMS is in a downtrend, momentum soft. $15 is the level overhead; $14.52 the first support below.
- A close below $14.52 on rising volume (breakdown).
- A bounce to $15 that fails (entry near resistance).
The brief
All readings
Levels that matter
Compare with…
Latest news
Hims & Hers Health (HIMS) stock analysis, November 15, 2026: bearish outlook with high conviction
Update, November 20, 2026
Since the November 15 report HIMS has slipped to $15.87, down 0.94% on the day and 19.56% over the past five days, while the S&P 500 rose 0.27% and the health‑care ETF XLV fell 4.88%, keeping the stock’s under‑performance to the market and sector intact.
The picture holds: the daily price remains below the critical 16.0 round resistance and still sits under the 50‑week SMA of 26.54, so the bearish, high‑conviction outlook remains aligned. The breakout level of a close below $15.0 has not been breached, and the stop at $16.5 (based on $16.0 plus a quarter of the 1.99 ATR) remains relevant. The target at $14.52 (52‑week low) is unchanged, and the 3‑to‑1 reward‑to‑risk test is still unmet.
Recent news adds nuance but does not shift the reading. On CNBC (Nov 18) the company announced a new peptide platform, and on NASDAQ (Nov 16) analysts highlighted a sharp post‑earnings drop. Neither event has moved the price above the key SMA levels or the $16.0 resistance, so the bearish picture remains unchanged. What would change the picture? A weekly close above the 26.54 SMA (or the swing‑zone at 27.41) would be required to alter the current stance.
Hims & Hers Health (HIMS) closed at $19.73 on November 13, a price that sits well below its 40‑week average and deep into a downtrend that began after a sharp peak at $30.64 on October 12. The daily price action follows the weekly decline, and the stock is lagging both the S&P 500 and the healthcare sector ETF XLV by more than 25% over the past 50 days. The balance of evidence points to a bearish stance with high conviction for the next two to six weeks.
Why it matters
The stock’s recent slide reflects a combination of broader market weakness and company‑specific pressure. Over the past five days HIMS fell 24.1%, while the S&P 500 rose 2.6% and XLV gained 2.2%, leaving the stock 26.3% underperforming its sector. That divergence suggests investors are penalising HIMS beyond the market’s overall health, likely because the price remains well under key technical levels and the company has not shown any catalyst to reverse the trend.
Technical context reinforces the downside bias. The price is below both the 50‑day simple moving average ($27.61) and the 200‑day average ($26.68), and the 14‑day RSI sits at 33.4, indicating oversold momentum but still within a bearish framework. Volume is 33.9% below its 20‑day average, implying a lack of buying interest even as the price approaches round support at $19.0.
Analyst expectations further underscore the disconnect. Thirteen analysts rate the stock as a “hold” with a mean price target of $28.31, a low of $23.0 and a high of $40.0. The current price is 30.3% below the mean target, a gap that mirrors the 35.6% drop from the recent peak. While the consensus does not signal a dramatic upside, the valuation spread suggests the market is pricing in continued weakness rather than a rapid recovery.
There is no recent news to explain the move; the news feed is empty, indicating the price action is driven by technical decay and sector rotation rather than a specific event. The debate among market participants is similarly quiet, with no published arguments for a near‑term rebound. In the absence of fresh information, the price action reflects pure market mechanics and the prevailing sentiment that HIMS remains vulnerable.
What the evidence says
On the long‑term horizon the thesis that HIMS is in a downtrend remains intact. The stock sits below its 40‑week average, the 52‑week low of $14.52 is still 35.9% away, and the weekly trend is clearly downward. The structure holds the price above $20.0, a round level that has historically attracted sellers on rallies, confirming that the downtrend is still in force.
For the next two to six weeks the balance of evidence leans negative with high conviction. The assessment notes three of four conviction points: the daily trend aligns with the weekly downtrend, the stock lags the S&P 500 by 27.5% over 50 days, and it lags XLV by 34.1% over the same period. The breakout math points to a downside breakout if the price closes below $19.0, with a stop at $20.59 and a target at the 52‑week low of $14.52, offering a reward‑to‑risk of 2.8. The math does not meet a 3‑to‑1 risk‑reward, but the downside case remains stronger than the upside.
The strongest case against a bearish reading would be a rapid swing back above the $27.41 swing zone on a weekly close, which would signal a reversal of the weekly trend. However, that scenario requires a price move of more than 40% from current levels, a swing that is not supported by the current volume or momentum indicators.
Levels that matter
The structure holds the stock above $20.0, a round level where sellers have repeatedly stepped in during prior rallies. The weekly trend would be considered ended if the price closes above $27.41, a swing‑zone level that marks the top of the recent range. Below that, the weekly downtrend remains intact.
The breakout level is a daily close under $19.0. If that occurs, the stop is set at $20.59, derived from $20.0 plus a quarter of the 14‑day ATR ($2.35). The primary target is the 52‑week low of $14.52, yielding a reward‑to‑risk of 2.8. Because the math does not achieve a 3‑to‑1 ratio, a price move to about $13.0 would be needed to reach that threshold, which is well below the current support zone.
What would change the picture
A weekly close above $27.41 would alter the current outlook, as it would signal that the weekly downtrend has been broken. The non‑price catalyst that could trigger such a move would be a materially better‑than‑expected earnings report on November 10, delivering revenue or profit growth that materially exceeds consensus expectations.
What to watch
- November 10 earnings – focus on the earnings per share figure and any forward guidance that deviates sharply from the consensus.
- Sector developments – watch for any regulatory changes or major product approvals in the specialty and generic drug space that could lift XLV and, by extension, HIMS.
- Valuation – the stock trades roughly 30% below the mean analyst target of $28.31, a spread that will narrow only if the price moves toward that mean.